Found: 189
Select item for more details and to access through your institution.
Use of fumaric acid esters in psoriasis.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Ustekinumab.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Consistency of Infliximab Response across Subgroups of Patients with Psoriasis: Integrated Results from Randomized Clinical Trials.
- Published in:
- Psoriasis Forum, 2007, n. 1, p. 21, doi. 10.1177/247553030713a00104
- By:
- Publication type:
- Article
Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 9, p. 953, doi. 10.1001/jamadermatol.2024.2463
- By:
- Publication type:
- Article
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Correction to: Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 6, p. 913, doi. 10.1007/s40257-023-00809-0
- By:
- Publication type:
- Article
Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis.
- Published in:
- American Journal of Clinical Dermatology, 2022, v. 23, n. 1, p. 1, doi. 10.1007/s40257-021-00639-y
- By:
- Publication type:
- Article
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
- Published in:
- American Journal of Clinical Dermatology, 2020, v. 21, n. 6, p. 881, doi. 10.1007/s40257-020-00555-7
- By:
- Publication type:
- Article
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
- Published in:
- American Journal of Clinical Dermatology, 2019, v. 20, n. 1, p. 155, doi. 10.1007/s40257-018-0396-z
- By:
- Publication type:
- Article
Erratum to: Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.
- Published in:
- American Journal of Clinical Dermatology, 2017, v. 18, n. 4, p. 591, doi. 10.1007/s40257-017-0295-8
- By:
- Publication type:
- Article
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.
- Published in:
- American Journal of Clinical Dermatology, 2017, v. 18, n. 3, p. 405, doi. 10.1007/s40257-017-0258-0
- By:
- Publication type:
- Article
Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials.
- Published in:
- American Journal of Clinical Dermatology, 2016, v. 17, n. 1, p. 79, doi. 10.1007/s40257-015-0161-5
- By:
- Publication type:
- Article
The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis.
- Published in:
- American Journal of Clinical Dermatology, 2011, v. 12, n. 5, p. 321, doi. 10.2165/11587890-000000000-00000
- By:
- Publication type:
- Article
Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 2, p. 1276, doi. 10.3390/ijms24021276
- By:
- Publication type:
- Article
Which PASI Outcome Is Most Relevant to the Patients in Real-World Care?
- Published in:
- Life (2075-1729), 2021, v. 11, n. 11, p. 1151, doi. 10.3390/life11111151
- By:
- Publication type:
- Article
Treatment Satisfaction in Psoriasis: Development and Use of the PsoSat Patient Questionnaire in a Cross-Sectional Study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Epidemiology and Comorbidity in Children with Psoriasis and Atopic Eczema.
- Published in:
- Dermatology (10188665), 2015, v. 231, n. 1, p. 35, doi. 10.1159/000381913
- By:
- Publication type:
- Article
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA).
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 2, p. 453, doi. 10.1007/s13555-023-01092-x
- By:
- Publication type:
- Article
Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 11, p. 2721, doi. 10.1007/s13555-023-01026-7
- By:
- Publication type:
- Article
Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 203, doi. 10.1007/s13555-021-00658-x
- By:
- Publication type:
- Article
Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 233, doi. 10.1007/s13555-021-00654-1
- By:
- Publication type:
- Article
Correction to: Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 61, doi. 10.1007/s13555-021-00635-4
- By:
- Publication type:
- Article
Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 6, p. 1965, doi. 10.1007/s13555-021-00602-z
- By:
- Publication type:
- Article
Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 2, p. 571, doi. 10.1007/s13555-021-00504-0
- By:
- Publication type:
- Article
Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
- Published in:
- Dermatology & Therapy, 2020, v. 10, n. 5, p. 1099, doi. 10.1007/s13555-020-00428-1
- By:
- Publication type:
- Article
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.
- Published in:
- Dermatology & Therapy, 2020, v. 10, n. 3, p. 431, doi. 10.1007/s13555-020-00367-x
- By:
- Publication type:
- Article
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure.
- Published in:
- Dermatology & Therapy, 2020, v. 10, n. 1, p. 133, doi. 10.1007/s13555-019-00340-3
- By:
- Publication type:
- Article
Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.
- Published in:
- Experimental Dermatology, 2015, v. 24, n. 7, p. 529, doi. 10.1111/exd.12710
- By:
- Publication type:
- Article
CD40 ligation during dendritic cell maturation reduces cell death and prevents interleukin-10-induced regression to macrophage-like monocytes.
- Published in:
- Experimental Dermatology, 2008, v. 17, n. 3, p. 177, doi. 10.1111/j.1600-0625.2007.00668.x
- By:
- Publication type:
- Article
Who is really in control of skin immunity under physiological circumstances – lymphocytes, dendritic cells or keratinocytes?
- Published in:
- 2006
- By:
- Publication type:
- Other
The maturation-dependent production of interleukin-16 is impaired in monocyte-derived dendritic cells from atopic dermatitis patients but is restored by inflammatory cytokines TNF-α and IL-1β.
- Published in:
- Experimental Dermatology, 2004, v. 13, n. 12, p. 740, doi. 10.1111/j.0906-6705.2004.00251.x
- By:
- Publication type:
- Article
Psoriasis - New Insights Into Pathogenesis and Treatment.
- Published in:
- Deutsches Ärzteblatt International, 2009, v. 106, n. 1/2, p. 4
- By:
- Publication type:
- Article
Isolating and maintaining highly polarized primary epithelial cells from normal human duodenum for growth as spheroid-like vesicles.
- Published in:
- In Vitro Cellular & Developmental Biology Animal, 1997, v. 33, n. 7, p. 536, doi. 10.1007/s11626-997-0096-0
- By:
- Publication type:
- Article
SARS‐CoV‐2 infection among psoriasis patients in Germany: Data from the German registries PsoBest and CoronaBest.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2024, v. 22, n. 7, p. 965, doi. 10.1111/ddg.15433
- By:
- Publication type:
- Article
SARS‐CoV‐2‐Infektionen bei Patienten mit Psoriasis in Deutschland: Daten aus den deutschen Registern PsoBest und CoronaBest.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2024, v. 22, n. 7, p. 965, doi. 10.1111/ddg.15433_g
- By:
- Publication type:
- Article
Generalized pustular psoriasis: overview of the status quo and results of a panel discussion.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2022, v. 20, n. 6, p. 753, doi. 10.1111/ddg.14764
- By:
- Publication type:
- Article
Generalisierte pustulöse Psoriasis: Überblick zum Status quo und Ergebnisse einer Diskussionsrunde.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2022, v. 20, n. 6, p. 753, doi. 10.1111/ddg.14764_g
- By:
- Publication type:
- Article
Molekulardiagnostik in der Dermatologie: Eine Online‐Umfrage zur Untersuchung von Nutzung, Hürden und Anforderungen in Deutschland.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2022, v. 20, n. 3, p. 287, doi. 10.1111/ddg.14659_g
- By:
- Publication type:
- Article
Molecular diagnostics in dermatology: An online survey to study usage, obstacles and requirements in Germany.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2022, v. 20, n. 3, p. 287, doi. 10.1111/ddg.14659
- By:
- Publication type:
- Article
Deutsche S3‐Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm – Teil 2: Therapiemonitoring, besondere klinische Situationen und Komorbidität.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2021, v. 19, n. 7, p. 1092, doi. 10.1111/ddg.14507_g
- By:
- Publication type:
- Article
German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 2: Treatment monitoring and specific clinical or comorbid situations.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2021, v. 19, n. 7, p. 1092, doi. 10.1111/ddg.14507
- By:
- Publication type:
- Article
Deutsche S3‐Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm – Teil 1: Therapieziele und Therapieempfehlungen.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2021, v. 19, n. 6, p. 934, doi. 10.1111/ddg.14508_g
- By:
- Publication type:
- Article
German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 1: Treatment goals and treatment recommendations.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2021, v. 19, n. 6, p. 934, doi. 10.1111/ddg.14508
- By:
- Publication type:
- Article
COVID‐19 und Auswirkungen auf dermatologische und allergologische Erkrankungen.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2020, v. 18, n. 8, p. 815, doi. 10.1111/ddg.14195_g
- By:
- Publication type:
- Article
COVID‐19 and implications for dermatological and allergological diseases.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2020, v. 18, n. 8, p. 815, doi. 10.1111/ddg.14195
- By:
- Publication type:
- Article
S3‐Leitlinie zur Therapie der Psoriasis vulgaris Update – Kurzfassung Teil 1 – Systemische Therapie.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2018, v. 16, n. 5, p. 645, doi. 10.1111/ddg.13516_g
- By:
- Publication type:
- Article
S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 2 – Special patient populations and treatment situations.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2018, v. 16, n. 6, p. 806, doi. 10.1111/ddg.13538
- By:
- Publication type:
- Article